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Abstract
H-ferritin (HFn) nanocarrier is emerging as a promising theranostic platform for tumor diagnosis and therapy, which
can speciﬁcally target tumor cells via binding transferrin receptor 1 (TfR1). This led us to investigate the therapeutic
function of TfR1 in GC. The clinical signiﬁcance of TfR1 was assessed in 178 GC tissues by using a magneto-HFn
nanoparticle-based immunohistochemistry method. The therapeutic effects of doxorubicin-loaded HFn nanocarriers
(HFn-Dox) were evaluated on TfR1-positive GC patient-derived xenograft (GC-PDX) models. The biological function of
TfR1 was investigated through in vitro and in vivo assays. TfR1 was upregulated (73.03%) in GC tissues, and reversely
correlated with patient outcome. TfR1-negative sorted cells exhibited tumor-initiating features, which enhanced tumor
formation and migration/invasion, whereas TfR1-positive sorted cells showed signiﬁcant proliferation ability. Knockout
of TfR1 in GC cells also enhanced cell invasion. TfR1-deﬁcient cells displayed immune escape by upregulating PD-L1,
CXCL9, and CXCL10, when disposed with IFN-γ. Western blot results demonstrated that TfR1-knockout GC cells
upregulated Akt and STAT3 signaling. Moreover, in TfR1-positive GC-PDX models, the HFn-Dox group signiﬁcantly
inhibited tumor growth, and increased mouse survival, compared with that of free-Dox group. TfR1 could be a
potential prognostic and therapeutic biomarker for GC: (i) TfR1 reversely correlated with patient outcome, and its
negative cells possessed tumor-aggressive features; (ii) TfR1-positive cells can be killed by HFn drug nanocarrier. Given
the heterogeneity of GC, HFn drug nanocarrier combined with other therapies toward TfR1-negative cells (such as
small molecules or immunotherapy) will be a new option for GC treatment.
Introduction
Gastric cancer (GC) is one of the most common types of
cancer and leading causes of cancer-related death
worldwide1. Nearly half of diagnosed GC is in China
annually around the world2. Chemotherapy is one of the
most commonly used methods for pre- or postoperation
of the GC treatment, and this therapy strategy has been
demonstrated to provide survival beneﬁt or decrease
lymph node metastasis to patients3–5. However, che-
motherapy drugs will bring serious side effects to patients
by their indiscriminate drug distribution and severe
toxicity. Although many efforts have been made to
investigate the molecular mechanisms of GC, few clearly
targeted drugs are developed to treat GC patients in the
clinic. It has been reported that targeted HER2 (human
epidermal growth factor receptor 2) and VEGFR2 (vas-
cular endothelial growth factor receptor 2) inhibitor drugs
could prolong the survival of some GC patients6,7. How-
ever, this part of the population accounts for only about
© The Author(s) 2020
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Wenguo Jiang (Jiangw@cardiff.ac.uk) or
Xiyun Yan (yanxy@ibp.ac.cn) or Jiafu Ji (jijiafu@hsc.pku.edu.cn)
1Key Laboratory Carcinogenesis and Translational Research (Ministry of
Education/Beijing), Division of Gastrointestinal Cancer Translational Research
Laboratory, Peking University Cancer Hospital & Institute, Beijing, China
2Key Laboratory of Protein and Peptide Pharmaceutical, Chinese Academy of
Sciences and University of Chinese Academy of Sciences, Beijing, China
Full list of author information is available at the end of the article.
These authors contributed equally: Xiaojing Cheng, Kelong Fan, Lin Wang
Edited by J.E. Ricci
Ofﬁcial journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
20% of GC patients. There is more space for GC to dig
targeted drugs or methods for improving the treatment.
To overcome this challenge, nanocarriers give such an
advantage to carry drugs to preferentially loci, thus
increasing drug aggregation and reducing side effects8–10.
Previous study indicated that H-ferritin (HFn) as a
nanocarrier can speciﬁcally bind to transferrin receptor 1
(TfR1 or CD71, in human), which guarantees iron supply
by binding of iron-loaded transferrin and ferritin, even
like a gate for pathogen selection to enter cells11–14.
Mammalian ferritin is a natural spherical iron-storage
protein, and two types of ferritin exist, namely, heavy-
chain ferritin (HFn) and light-chain ferritin (L-ferritin,
LFn)13,15. However, only HFn has been shown to target
human malignant cells through its receptor TfR113,16.
Although the receptor of LFn in mice has been conﬁrmed
as Scara517,18, its receptor in human has not been clearly
elucidated. Recent studies indicated that HFn nano-
carriers can encapsulate iron oxide nanoparticles (mag-
netoferritn, M-HFn) and load drugs by TfR1-mediated
speciﬁc binding without extra modiﬁcation10,12. It can be
used in diagnostic and targeted therapy in tumor, and
even transverse the blood–brain barrier to kill glioma
tumor cells, with reduced toxicity and side effects and
high tolerated dose13.
Previous study indicated that doxorubicin-loaded HFn
nanocarrier (HFn-Dox) has a ten-fold higher drug accu-
mulation, lower drug exposure of normal organs, and
more efﬁciently cleared from the body compared with free
Dox in mouse treatment model10. Therefore, in this study,
we ﬁrst investigated the clinical role of TfR1 on GC. We
found that TfR1 was highly expressed in GC cells, and
reversely correlated with the patient poor survival. TfR1-
negative sorted GC cells showed tumor-initiating features.
Knockout of TfR1 by CRISPR displayed immune escape
when treated by IFN-γ, and activated Akt and STAT3-
signaling pathways. Then for measuring the therapeutic
value of HFn-Dox on TfR1-positive cells, we examined
the effect of HFn-Dox in TfR1-positive GC patient-
derived xenograft (GC-PDX) models. Taken together, our
data suggest that TfR1 might be a potential identiﬁcation
biomarker in GC-targeted therapy. As the malignant and
heterogeneity nature of tumor, combination therapy
might achieve a better treatment effect: one with HFn
drug nanocarrier system targeted to TfR1-positive
cells; the other with inhibitors antagonistic to TfR1-
negative cells.
Results
Correlation of TfR1 with clinicopathological parameters
TfR1 expression was evaluated by using a magneto-HFn
(M-HFn) nanoparticle-based immunohistochemistry (IHC)
method in GC and adjacent noncancerous mucosa tissues.
TfR1 was expressed highly in tumor cells (Fig. 1a). We also
validated the consistency of tumor detection with the tra-
ditional IHC, with an anti-TfR1 antibody in GC tissues (Fig.
S1). TfR1 was positive in 130 of 178 tumor tissues, and 15 of
95 in the noncancerous mucosa tissues (73.03% vs. 15.79%,
P < 0.0001), respectively. In paired tissues, the TfR1
expression was 75.27% vs. 13.99% (GC vs. paired non-
cancerous tissues, P < 0.0001). (Fig. 1b). The level of TfR1
mRNA in normal and GC specimens was analyzed by the
Gene Expression Omnibus (GEO) database (GES13861 and
GES63089), which indicated that TfR1 mRNA level was
signiﬁcantly higher in GC tissues compared with adjacent
noncancerous mucosa tissues (P < 0.0001 and P < 0.0001,
respectively) (Fig. 1c). We measured the expression level of
TfR1mRNA in 11 pairs of primary GC tissues, and matched
adjacent noncancerous mucosa tissues. Consistent with
these results, a relatively higher expression of TfR1 was
found in GC tissues compared with its matched adjacent
noncancerous mucosa tissues (Fig. 1d).
Among the TfR1 protein levels in GC patients, a higher
proportion of tumors located at the distal region was TfR1
positive than that of tumors in the proximal region (61.2%,
79/129 vs. 39.6%, 19/48, P= 0.010, Fig. 1e). However,
there was no signiﬁcant correlation with age, gender,
lymph node metastasis, depth of invasion, distant metas-
tasis, and differentiation, gross type, tumor size, Lauren,
and tumor-node-metastasis (TNM) stage of GC patients.
Detailed data are shown in Table S1.
TfR1 expression reversely correlated with poor prognosis
in primary GC
Overall GC patient survival in TfR1 mRNA level was
analzyed by Kaplan–Meier method, using the online tool
(http://kmplot.com/analysis), showed that a high level of
TfR1 expression was signiﬁcantly associated with a better
overall survival (OS) in GC patients (Fig. 1f). Similar
results were detected in our data based on protein levels
of TfR1 (P= 0.003 (OS) and 0.004 (PFS, progression-free
survival), respectively; Fig. 1g). For the protein level of
TfR1, the median 5-year OS time was 34.89 ± 2.42 months
for TfR1-low patients and 44.15 ± 2.11 months for TfR1-
high patients, respectively, and the median PFS time was
31.68 ± 2.57 vs. 37.66 ± 2.22 months, respectively.
The univariate Cox’s model for 5-year survival of GC
patients revealed that TfR1 expression was one of the
prognostic factors (hazard ratio (HR)= 0.533; 95% con-
ﬁdence interval (CI): 0.348–0.817; P= 0.004), and the
other prognostic factors included lymph node metastasis
(P < 0.001), depth of invasion (P < 0.001), distant metas-
tasis (P < 0.001), and tumor size (P < 0.001). Using the
multivariate Cox’s model, TfR1 was shown to be a novel
independent prognostic factor of 5-year OS (HR= 0.450;
95% CI: 0.286–0.708; P= 0.001), compared with other
independent prognostic factors including lymph node
metastasis (P < 0.001), depth of invasion (P= 0.016),
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distant metastasis (P < 0.001), and tumor size (P= 0.017).
Detailed data are shown in Table 1.
HFn-encapsulated Dox showed superior antitumor effects
on GC-PDX tumor
For the therapy effects of HFn nanocarriers encapsu-
lating Dox, we selected TfR1-positive GC-PDX models
treated with Dox-loaded HFn. The size-exclusion chro-
matogram of HFn-Dox and unloaded HFn is shown in Fig.
S2. PDX models maintain the same genetic characteristics
(methylation status, mutations, and resistance to therapy)
observed in the patient from whom they were derived19,20.
Hematoxylin–eosin (HE) staining showed the similarity of
histological features between the patient tissue and its
derived ones (Fig. 2a). HFn-Dox group signiﬁcantly
inhibited the tumor growth compared with free-Dox and
HFn groups (108.99 ± 4.05 mm3 vs. 717.66 ± 218.00mm3
and 1229.61 ± 365.05mm3), presenting the tumor growth
inhibition (TGI) rate of 91.1% for HFn-Dox compared
with that of 41.6% for free Dox (P < 0.01) (Fig. 2b). There
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Fig. 1 TfR1 protein expression in GC patients reversely correlated with poor prognosis. a Different staining scores with M-HFn nanoparticles
detecting TfR1 in GC tissues by IHC, scale bars: 50 µm. b Expression level of TfR1 protein in GC and their (or matched) adjacent noncancerous tissues.
c TfR1 mRNA expression was signiﬁcantly upregulated in GC tissues compared with adjacent normal mucosa in GES63089 and 13861 from GEO
datasheets, respectively. d Ratio (T/N) of TfR1 mRNA expression in 11 paired primary GC patients, which was determined by qPCR (lower panel). Their
expression levels were normalized by an internal control (GAPDH). e IHC staining that indicated high TfR1 protein expression was signiﬁcantly
associated with location of GC. f Kaplan–Meier survival analysis of OS obtained from public gene expression datasets. g Kaplan–Meier analysis of 5-
year survival with low vs. high TfR1 protein expression status (left); Kaplan–Meier survival analysis of DFS with low vs. high TfR1 protein expression
status (right). *P < 0.05; **P < 0.01; ****P < 0.0001.
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was also a signiﬁcant improvement of survival for the
HFn-Dox group compared with free-Dox and HFn groups
(55 days vs. 26 and 27 days, both P < 0.01) (Fig. 2c), and
with less weight loss in the HFn-Dox group compared with
that of other two groups (Fig. 2d). Cardiotoxicity is a major
limiting factor in clinical Dox-based therapy. Our work
thus adds evidence that HFn-Dox treatment can sub-
stantially decrease in Dox-associated cardiomyopathy.
This was also shown in a recent study that injections of
HFn-Dox up to 20mg/kg doses did not result in sig-
niﬁcant cardiotoxicity10.
Considering the drug effect in tumor tissues, we con-
ducted histological analysis by using two proliferation
markers: PCNA and Ki67, and TUNEL staining for cell
apoptosis detection (Fig. 2e). There were less proliferation
and more extensive apoptosis in the HFn-Dox group
compared with free-Dox and HFn protein group,
demonstrating that HFn-Dox possesses an obviously
killing role in GC cells.
TfR1-negative expression cells possessed tumor-initiating
properties through in vitro and in vivo assays
Given TfR1 clinical results and the tumor heterogeneity,
we further investigated the function of TfR1 differentially
expressed cells. We analyzed expression proﬁles within
SGC7901 TfR1− and TfR1+ sorted cells using RNA-seq
(Fig. 3a). Signiﬁcant signaling pathway and volcano plot
illustrated the differentially expressed genes between TfR1−
and TfR1+ sorted cells (fold change > 2.0 or <2.0; Q value
< 0.05), which mainly focused on molecules participating
in pluripotency of stem cells, drug resistance, and
cytokine–cytokine receptor interaction (Table S2).
TfR1 was overexpressed in six GC cells (BGC823,
SGC7901, AGS, HGC27, N87, and GES1) (Fig. 3b).
Table 1 Univariate and multivariate Cox’s models for 5-year overall survival of gastric cancer .patients
Variables Gastric cancer univariate analysis Gastric cancer multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 0.883 0.113
≤60 vs. >60 1.032 0.676–1.577 1.452 0.915–2.305
Gender 0.295 0.109
Male vs. female 0.782 0.493–1.240 0.670 0.410–1.094
Lymph node metastasis <0.001 <0.001
No vs. N1+ 2+ 3 18.465 5.825–58.531 11.947 3.726–38.311
Depth of invasion <0.001 0.016
T1+ 2 vs. T2+ 3 16.146 3.969–65.690 5.815 1.388–24.366
Distant metastasis <0.001 <0.001
M0 vs. M1 7.084 3.972–12.632 7.711 3.957–15.026
Differentiation 0.298
Poor vs. moderate+ good 0.797 0.520–1.222
Gross type 0.161
Ulcerative type vs. others 0.636 0.337–1.198
Tumor size <0.001 0.017
≤5.0 cm vs. >5.0 cm 2.624 1.700–4.050 1.720 1.101–2.688
Location 0.122
Distant vs. proximal 0.700 0.446–1.100
Lauren
Diffuse vs. intestinal 1.395 0.753–2.583 0.290
Diffuse vs. mixed 0.934 0.534–1.635 0.811
TfR1 0.004 0.001
Low vs. high 0.533 0.348–0.817 0.450 0.286–0.708
Proximal cardiac and gastroesophageal junction, distal gastric.
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TfR1-negative sorted cells promoted the cell migration
and invasion in HGC27 and SGC7901 cells by wound
healing and Boyden chamber invasion assays (Fig. 3c, d),
respectively. TfR1− sorted cells displayed a higher
colony-forming efﬁciency compared with their respec-
tive counterpart TfR1+ sorted cells (Fig. 3e). Then to
conﬁrm the malignant property of these two sorted
TfR1 populations, we compared the tumorigenic ability
of TfR1− and + sorted cells. We found that 3000 TfR1−
sorted cells formed tumors in three out of ﬁve subjects
in both HGC27 and SGC7901 cells, and even fewer cells
(300) were still able to form tumors. Nevertheless, there
was no tumor formation with the corresponding num-
ber of TfR1+ sorted cells during the observed days (Fig.
3f). Furthermore, qPCR results indicated that the
expression level of Sox2, Nanog, Oct4, and CACNA2D1
mRNA was higher in TfR1− sorted cells compared with
TfR1+ ones (Fig. 3g). However, TfR1− sorted cells
showed signiﬁcantly lower cell proliferation ability
compared with TfR1+ sorted cells (Fig. 3h). These
results demonstrate that GC cells with the absence of
TfR1 possess tumor-initiating properties.
As TfR1− sorted cells had progenitor cell properties, we
selected the calcium channel α2δ1 subunit (CACNA2D1)
as a target for inhibiting the movements of TfR1− sorted
cells, which is one of the tumor-initiating molecules
(TIMs) found in recurrent hepatocellular carcinoma21.
First, we examined CACNA2D1 and CD44 markers in
both sorted TfR1 cells using immunoﬂuorescence (IF).
TfR1− sorted cells expressed higher levels of these
molecules (Fig. 4a). Furthermore, we selected 1B50-1, a
monoclonal antibody targeting CACNA2D1, to explore
treatment effects against TfR1− sorted cells. As shown in
Fig. 4b, c, IB50-1 showed a signiﬁcant suppressive effect
on the migration and invasion of the TfR1− sorted cells,
puriﬁed from HGC27 and SGC7901 cells.
TfR1-knockout cells enhanced responsiveness to IFN-γ
treatment
GSEA with TCGA STAD data on hallmark or KEGG
gene sets indicated that myogenesis and primary
immunodeﬁciency-related gene signatures were positively
correlated in TfR1 low-expressed cells (Fig. 5a). To
investigate the function of TfR1 in GC cells, we selected
TfR1-knockout cells with CRISPR–Cas9, and conﬁrmed its
expression with ﬂow cytometry analysis (Fig. 5b). To further
investigate the function of TfR1 in GC cells, knockout of
TfR1 in BGC823 and SGC7901 cells markedly promoted
cell invasion and clonogenicity by Matrigel invasion and
colony formation assays (Fig. 5c, d). As primary
immunodeﬁciency-related genes were correlated with TfR1
low-expressed cells, we detected fold changes of PD-L1,
CXCL9, and CXCL10 mRNA levels in TfR1-knockout cells,
which were enhanced after IFN-γ treatment (Fig. 5e).
Recent studies demonstrated that interferon pathway may
improve the immune checkpoint blockade therapy22. But
the correlation of TfR1-negative cells and the immune
checkpoint blockade therapy needs to be further elucidated.
Moreover, as CD44 is used as a marker for cells with stem-
like characteristics23,24, stratiﬁcation of patient groups based
on double expression of CD44+ and TfR1− improved the
single predictive value of CD44 in patients with OS and PFS
(Fig. S3a). Knockout of TfR1 in GC cells promoted the
expression of mesenchymal markers (N-cadherin and
Snail), and activated AKT and STAT3 signaling, as shown
by Western blot (Fig. 5f).
Analysis of TfR1-related tumor–genome features based on
TCGA datasets
We performed gene set enrichment analysis (on Hall-
mark gene sets) to identify major biological processes
using the Cancer Genome Atlas (TCGA) RNA-seq data-
sets (quartile highest and lowest TfR1 expression samples)
(Fig. S3b). KEGG gene set analysis revealed that vascular
smooth muscle contraction, calcium-signaling pathway,
and primary immunodeﬁciency signiﬁcantly correspond
to TfR1 low-expression cases (Fig. S3b1). However, cell
cycle, DNA replication, and RNA degradation (Fig. S3b2)
correspond to TfR1 high-expression cases. In addition, we
found that CD8A and CD8B were reversely correlated
with TfR1 (TFRC) expression in TCGA RNA-seq datasets
(Fig. S3c). Low TfR1 mRNA levels were associated with a
substantial worse survival in GC patients with high CD8
mRNA levels divided by the mean of CD8 (CD8A+
CD8B)/2, but not in the low CD8 mRNA group (Wil-
coxon P= 0.0489 and 0.4298, respectively) (Fig. S3d).
(see ﬁgure on previous page)
Fig. 3 GC cells with the absence of TfR1 possess tumor-initiating like properties through in vitro and in vivo assays. a RNA-seq proﬁles for
sorted TfR1-negative and -positive cells were analyzed. Signiﬁcant signaling pathway (left panel) and volcano plot illustrated the differentially
expressed genes between TfR1-negative and -positive cells (right panel, fold change > 2.0 or <2.0; Q value < 0.05). Blue, green, and red colors
indicated various genes belonging to different groups of cell processes. b TfR1 was overexpressed in six GC cells (BGC823, SGC7901, AGS, HGC27,
N87, and GES1). c–e Absence of TfR1 promoted cell migration, invasion, and colonogenicity by wound-healing assay, Boyden chamber invasion
assay, and colony formation assay. Scale bar: 100 µm. f Analysis of TfR1 sorted ± cell tumorigenity following transplantation with different numbers of
cells into NOD/SCID mice. g Sox2, Nanog, Oct4, and CACNA2D1 mRNA relative expression was determined by qPCR. Their expression levels were
normalized by an internal control (GAPDH). h TfR1-positive sorted cells showed obviously cell proliferation ability detected by real-time RTCA
instrument. *P < 0.05; **P < 0.01, ***P < 0.001.
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Discussion
This study was the ﬁrst to demonstrate the clinical
value of TfR1 based on HFn nanoparticle in GC as a
potential prognostic indicator and therapeutic target.
We used HFn nanoparticle to assess the clinical value of
TfR1 in GC, and found that its expression is reversely
associated with poor prognosis of GC patients, inde-
pendent of their clinicopathological characteristics.
Employing HFn as a nanocarrier (binding with TfR1 in
the cell membrane), we ﬁrst demonstrated that HFn-
Dox can signiﬁcantly improve the treatment efﬁcacy of
Dox to the GC-PDX model. Within the treatment cycle,
the HFn-Dox almost completely inhibited the growth
of tumor, and HFn-Dox treatment signiﬁcantly increased
the survival time and OS rate of tumor-bearing mice. As
tumor cells are a highly heterogeneous population, we
further testiﬁed that TfR1-negative GC cells possessed the
tumor-initiating cells (TIC) properties and immune
escape features through ﬂuorescence-activated cell sort-
ing (FACS) or CRISPR knockout through in vitro and
in vivo assays.
IHC assays or mRNA expression analyzed with GEO
datasets indicated that TfR1 expression in GC tissues was
signiﬁcantly higher than its expression in adjacent non-
cancerous mucosa tissues. Just as conventional antibody-
based immunohistochemical assays for cancer detection, this
novel M-HFn nanoparticle-based method identifying TfR1-
positive cells can also distinguish tumors from normal tis-
sues12. Previous studies demonstrated that transferrin (Tf) is
an essential component in cell growth and iron-requiring
metabolic processes25,26; thus, TfR1 is more highly expressed
on rapidly growing cells such as on tumor cells27,28.
Although this is the ﬁrst study on GC, the ﬁndings on
the expression pattern here bear similarities to previous
reports that TfR1 can be endogenously overexpressed in a
variety of cancers, including lung29,30, colon31, pancreas32,
and breast33. It is interesting to note the ﬁnding that TfR1
high expression signiﬁcantly correlated with a favorable
OS of GC patients. This phenomenon contrasts with that
seen with breast cancer, in which TfR1 has been indicated
as a poor marker for prognosis predicting breast cancer
patients who respond to tamoxifen34. However, Ohkuma
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et al.35 reported that gastric adenosquamous cancer cells
with the absence of TfR1 (CD71) possess tumor-initiating
cell properties. This phenomenon might explain from the
side that GC cells with TfR1 low expression have malig-
nant features. Furthermore, several previous studies
reported TfR1 deﬁciency in stem cells, including malig-
nant leukemic36,37, keratinocyte38, and hematopoietic
stem cells39.
Analysis of tumor–genome features (GSEA on KEGG
and hallmark gene sets) based on RNA-seq and TCGA
datasets revealed that the upregulated genes were enri-
ched in signaling pathways regulating the pluripotency of
stem cells, cytokine–cytokine receptor interaction, myo-
genesis, and primary immunodeﬁciency, which was sig-
niﬁcantly enriched in TFRC low-expression cells or
groups. PD-L1, CXCL9, and CXCL10 mRNA expression
level was detected through fold changes (the highest
changes are 100-fold) in TfR1 low cells compared with its
high cells when stimulated by IFN-γ. These might be
hinted for us that TfR1 low cells possessed the resistance
of antitumor immune response40,41. However, the corre-
lation of TfR1-negative cells and the immunotherapy
needs to be further elucidated. As TfR1-negative cells
displayed stem cell-like features, we found that 1B50-1
targeting CACINA2D1 could substantially inhibit TfR1-
negative cell movement using Boyden chamber assay.
These results guided us to choose a combination of this
different class of agents (HFn chemicals, inhibitors for
TIMs, and immune checkpoint blockade) for clinical
application. Just like the ongoing clinical trial, che-
motherapy, radiotherapy, and targeted therapy combine
with PD1 therapy42. Combination therapy represents an
effective strategy in treatment of cancer.
Our work provides an alternative approach for GC-
targeted therapy as another form of chemotherapy drugs:
(1) HFn nanocarriers with drugs could speciﬁcally kill GC
cells, which were TfR1 positive in a receptor-dependent
manner, and dozen-fold higher than their corresponding
normal cells43; (2) HFn (drug) nanocarriers could pas-
sively target GC by their unique diameter size (12 nm),
which is an ideal size for enhanced permeability and
retention effects of the vasculature (EPR effect); (3) based
on the feature of TfR1-negative cells, selecting other
antagonists (antibody or small molecules toward tumor-
initiating molecules) or immunotherapy as a combination
with HFn drug nanocarriers might be an ideal treatment
method for GC. A further validation of the combination
treatment needs to be explored in GC-PDX models.
This study has indicated that HFn-Dox nanocarriers
would be a beneﬁcial choice for patients with GC in this
context, but one marker alone will not truly reveal the
malignant nature of cancer tissues; combination antago-
nist to other inhibitors for TIMs or immunotherapy with
HFn drug nanocarrier systems might achieve a better
treatment effect. However, our current studies demon-
strated that TfR1 is a potential prognostic biomarker, and
HFn drug nanocarrier makes an ideal therapeutic
approach by targeting TfR1 in GC cells.
Materials and methods
GC patients and specimens
In total, 178 tissue specimens available for IHC analysis
from patients who underwent surgical resection during
2008–2011 at Peking University Cancer Hospital &
Institute were enrolled in this study. For IHC, each tissue
specimen was formalin-ﬁxed after resection, and then
embedded with parafﬁn. All the included patients have
histological diagnosis of GC, no neoadjuvant che-
motherapy, and complete clinical records. The TNM
stage of GC was classiﬁed according to the 8th edition of
classiﬁcation recommended by the American Joint
Committee on Cancer (AJCC). The median follow-up
duration of patients since the time of diagnosis was
39.96 months. In total, 85 patients died in the follow-up
period. All patients provided informed consent for
obtaining the tissue specimens. This study was approved
by the Clinical Research Ethics Committee of Peking
University Cancer Hospital & Institute, and all patients
involved in this study provided written informed consent.
Human HFn and magneto-HFn (M-HFn) protein
biosynthesis and puriﬁcation
The human HFn and M-HFn protein was synthesized
according to the descriptions of our previous reports12.
Detailed information about HFn and M-HFn biosynthesis
and puriﬁcation is described in the Supplementary
materials.
IHC and IF assays
The M-HFn nanoparticle-based IHC assay for GC tissues
was performed as previously reported12. As negative con-
trols, the sections were processed using the same protocol,
(see ﬁgure on previous page)
Fig. 5 TfR1-knockout cells displayed malignant properties and responded to IFN-γ treatment. a GSEA plot based on RNA-seq (upper panel) or
TCGA data (lower panel) indicated TfR1-negative cells correlated with developmental and immune deﬁciency. b TfR1-knockout cells were identiﬁed
by ﬂow cytometry analysis. c TfR1-knockout GC cells showed high invasion ability evaluated by RTCA real-time analysis instrument. d Knockout of
TfR1 increased cell colonogenicity. e PD-L1, CXCL9, and CXCL10mRNA level was enhanced in TfR1-knockout cells stimulated with IFN-γ (100 ng/ml) for
24 h. f The correlation of EMT- related markers, STAT3/AKT signaling with TfR1, were detected by Western blot. NES normalized enrichment score.
*P < 0.05; **P < 0.01; ***P < 0.001.
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except that they were not incubated with the M-HFn
nanoparticles. The staining of TfR1 was examined and
scored by two independent pathologists under microscopy,
who were blind to the patient clinical data. Immunor-
eactivity score together with the staining intensity were used
to assess the staining of TfR1. Finally, the staining levels of
TfR1 expression were ascribed to − and +, low expression;
++ and +++, high expression.
For IHC, primary antibodies were used to detect anti-
transferrin receptor antibody (anti-TfR1, Abcam, Cam-
bridge, UK), PCNA (Dako, Carpinteria, CA, USA), and
Ki67 antibody (Abcam, Cambridge, UK). For IF, primary
antibodies were used to detect CD44 (Dako, Carpinteria,
CA, USA) and 1B50-1 (anti-CACNA2D1), gifted by Prof.
Zhang, Peking University, with visualization using ﬂuor-
escein AF488 and AF594 (Jackson Alexa Fluor). DAPI was
used to detect nuclei.
Evaluation of antitumor activity in GC patient-derived
xenograft (GC-PDX) mouse model
Detailed information about formation of HFn-Dox
nanoparticles and their antitumor activity in the mouse
model was described in the supplementary materials. GC-
PDX mouse models were obtained from GC-PDX mouse
bank in Peking University Beijing Cancer Hospital.
Cell lines and FACS analysis
There were six GC cell lines (BGC823, SGC7901, AGS,
HGC27, N87, and GES1) and one HEK293FT cell line
used in this study. However, we focused on three cell lines
for the further functional study: HGC27, SGC7901, and
BGC823, which were obtained from Cell Research Insti-
tute, Shanghai, China. Cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (Gibco BRL) supplemented with
10% fetal bovine serum (FBS, Gibco BRL) in a humidiﬁed
atmosphere of 5% CO2 at 37 °C. Cell lines were authen-
ticated using short-tandem repeat analysis and tested for
mycoplasma contamination.
For FACS analysis, cells were dispersed, labeled, and
analyzed as protocol-described HFn12. HFn was directly
labeled with PE-Cy5 using Lightning-Link conjugation
kit following the protocol (Innova Biosciences Ltd.,
Cambridge, UK).
Tumorigenicity assay in NOD/SCID mice
For the tumorigenicity assay, 3 × 103 and 3 × 102 FACS
TfR1-negative and -positive cells were suspended in
200 µl of a 1:1 mix of DMEM and Matrigel (BD Bios-
ciences, Bedford, MA, USA), and transplanted sub-
cutaneously into the back leg of nonobese diabetic/Prkdc
severe combined immune-deﬁciency (NOD/SCID) mice
with approximated body weights of 18 g or so (5-week old,
Vitalriver, Beijing, China). Tumor formation was observed
three times every week.
All the animal experiments followed the Animal Care
Guidelines of Peking University Cancer Hospital &
Institute. NOD/SCID mice were randomly assigned into
four groups, and every group has three mice.
Cell invasion assay
Boyden chamber invasion assay
The upper chamber was coated or not with 2 mg/ml
Matrigel, and placed above the lower chamber with
DMEM supplemented with 10% FBS. Then FACS TfR1-
negative and -positive cells in serum-free DMEM (2 × 104
for both cells) were added to the upper chamber (coated
with Matrigel or not) or together with 1B50-1 antibody
(which detected CACNA2D1, gifted by Prof. Zhang),
which was given to these cells at the ﬁnal concentration of
17 µg/ml. After 18 and 36 h, migration and invasion were
performed in a 37 °C incubator. Three independent
experiments were performed.
RTCA xCELLigence real-time cell proliferation/invasion assay
An optimal number of cells per well (proliferation: 1.5 ×
103 cells/well in complete medium; invasion: SGC7901 for
3 × 104 and BGC803 for 4 × 104 cells/well with serum-free
medium in the upper chamber and complete medium in
the below chamber) were seeded as an initial experiment
in RTCA E-plate 16 or CIM-16 plates with 0.5 mg/ml
Matrigel (RTCA; xCELLigence Roche, Penzberg, Ger-
many). According to the xCELLigene manufacturer’s
instruction, baseline was measured. Plates were incubated
for 30 min at room temperature before starting the
measurements. Cell index was measured in a time-
resolved manner (every 10min during 65 h for prolifera-
tion assay; every 1 h during 40 h for invasion assay). Three
independent experiments were performed.
TUNEL assay
A TUNEL assay-based in situ cell death detection kit
(Roche Diagnostics GmbH, Mannheim, Germany) was
used to detect the apoptotic cell death that had occurred
in tumor grafts treated with HFn-Dox, Dox-free, and 1×
phosphate-buffered saline (PBS), respectively, following
the protocols recommended by the manufacturer. Slides
were mounted in 90% glycerol/PBS after staining nuclei
with DAPI. The slides were observed under a ﬂuorescent
confocal microscope (Leica, Wetzlar, Germany).
3D culturing
After sorting, TfR1-negative and -positive cells were
plated on 24-well plates coated with Matrigel (250 µl/well,
BD Biosciences) at a density of 200/well, and cultured for
2 weeks in DMEM medium supplemented with 10% FBS,
with the medium being changed every 48 h. Three inde-
pendent experiments were performed.
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RNA-seq analysis
Total RNA was isolated from sorted SGC7901 cells (TfR1
negative and positive) by ﬂow cytometry analysis. RNA
extraction was performed using RNeasy Micro Kit (Qiagen,
Germany) following the manufacturer’s protocol. Total RNA
was delivered to The Shanghai Biotechnology Corporation
for sequencing with Illumina HiSeq2500. FPKM (fragments
per kilobase of exon model per million mapped reads) was
used to standardize the gene expression level. Statistics for
differentially expressed genes were calculated by a q value ≤
0.05 and fold change ≥ 2 (RNA-seq: GSE143497).
LentiCRISPRv2-mediated sgRNA targeting TfR1 knockout
TfR1-knockout expression was established by
CRISPR–Cas9 targeting TfR1 in BGC823 and SGC7901 cell
lines. Lentivirus was produced by co-transfection of HEK2
93FT cells with LentiCRISPRv2, LentiCRISPRv2_sgTfR1-1,
and LentiCRISPRv2_sgTfR1-2, respectively, together with
lentiviral-packaging mix (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instruction, which was
transfected with Lipofectamine 2000 (Life Technologies).
For the detailed sequences of the sgRNA: sgTfR1-1: 5′-
CACCCG CTA TAC GCC ACA TAA CCC CC-3′; sgTfR1-
2: 5′-CACCCG CTG CAG CAC GTC GCT TAT AT-3′.
Stable TfR1-knockout cells were selected with puromycin
(1.0mg/ml) for 14 days after transfection for 48 h, and
successfully TfR1-knockout cell clones were identiﬁed by
ﬂow cytometry.
IFN-γ-responsive assay
An optimal number of cells (3 × 105) were plated on a
six-well plate for 12 h, then treated with IFN-γ (10 ng/ml)
for 24 h, and extracted with the corresponding RNA
to detect IFN-γ-inducible genes (PD-L1, CXCL9, and
CXCL10), the primers of these genes are listed in Table S3.
Three independent experiments were performed.
Gene set enrichment analysis (GSEA)
Data used for GSEA were accessible from RNA-seq
results and TCGA database (http://gdac.broadinstitute.
org/), and analyzed by the software GSEA v3.0 (http://
www.broadinstitute.org/gsea). The high and low groups of
TCGA GC specimens were separated by the upper and
lower 100 cases with TFRC expression level. False-
discovery rate was set at 0.20.
Statistics
Statistical analysis was carried out by SPSS20.0 software
(SPSS Inc., Chicago, IL). Chi-square test or Fisher’s exact
test was applied to assess the correlation between TfR1
expression and clinical parametric distribution in GC
patients. The association of TfR1 expression with OS and
PFS was analyzed by Kaplan–Meier curves and Log-rank
test. Univariate and multivariate analysis were used to
determine the potential prognostic factors with Cox
regression model. Mann–Whitney U test or Student’s
t test was performed to compare the signiﬁcant cell
function between two cell groups. The variance was
similar between the statistically compared groups. All
tests of statistical signiﬁcance were two-sided; P < 0.05
was judged as the statistically signiﬁcant level.
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